---
schema_version: "secwatch.filing_event.v1"
accession: "0001824293-25-000072"
form_type: "8-K"
ticker: "GRI"
cik: "0001824293"
company_name: "GRI Bio, Inc."
filed_at: "2025-05-15T23:59:59+00:00"
generated_at: "2026-05-21T05:32:53.372878+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# GRI Bio reports Q1 net loss $3.0M; GRI-0621 Phase 2a IPF trial on track for data in Q2/Q3 2025

## Summary
- Net loss of $3.0M for Q1 2025; R&D expenses $1.6M, G&A $1.4M.
- Cash $3.3M at March 31; subsequent $5M public offering; cash runway expected through Q3 2025.
- Phase 2a trial of GRI-0621: 6-week interim data (n=24) expected Q2 2025; topline data Q3 2025.
- Interim 2-week data in first 12 patients showed safety, no hyperlipidemia, and biomarker PRO-C3 suggestive of anti-fibrotic effect.
- Enrollment over two-thirds complete for overall Phase 2a IPF trial.

## SEC filing metadata
- accession: 0001824293-25-000072
- form_type: 8-K
- ticker: GRI
- cik: 0001824293
- company_name: GRI Bio, Inc.
- filed_at: 2025-05-15T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1824293/000182429325000072/0001824293-25-000072-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1824293/000182429325000072/val-20250515.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001824293-25-000072
- JSON: https://secwatch.observer/filing/0001824293-25-000072.json
- Plain text: https://secwatch.observer/filing/0001824293-25-000072.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.